{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:30:38Z","timestamp":1775025038272,"version":"3.50.1"},"reference-count":60,"publisher":"BMJ","issue":"Suppl 4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2013,9,11]]},"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:p>The delivery of effective antimicrobial therapy is essential for public health control of gonorrhoea, in the absence of a suitable vaccine. The antimicrobial agent chosen should have high efficacy and quality, lack toxicity and give &gt;95% success when given empirically. Guidelines, which are informed by surveillance data, are used to aid clinicians in their choice of appropriate agent. Historically, gonorrhoea treatment has been delivered as a single, directly observed dose but this has resulted in failure of successive antimicrobial agents which have been replaced by a new antimicrobial to which resistance has been rare or non-existing. Following the drift towards decreased susceptibility and treatment failure to the extended spectrum cephalosporins, and the lack of \u2018new\u2019 alternative antimicrobials, the threat of difficult to treat or untreatable gonorrhoea has emerged. The challenge of maintaining gonorrhoea as a treatable infection has resulted in national, regional and global response or action plans. This review discusses different approaches to the future treatment of gonorrhoea including; use of ceftriaxone, the injectable cephalosporin at increased dosage; dual antimicrobial therapy; use of drugs developed for other infections and use of older agents, directed by rapid point of care tests, to susceptible infections. Finally, it is considered whether the time is right to readdress the possibility of developing an effective gonococcal vaccine, given the major advances in our understanding of natural infection, molecular pathogenesis and the revolution in molecular biology techniques.<\/jats:p>","DOI":"10.1136\/sextrans-2012-050913","type":"journal-article","created":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T05:03:45Z","timestamp":1381295025000},"page":"iv52-iv56","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Current and future treatment options for gonorrhoea"],"prefix":"10.1136","volume":"89","author":[{"given":"Catherine A","family":"Ison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,10,8]]},"reference":[{"key":"2024051410042031000_89.Suppl_4.iv52.1","unstructured":"World Health Organization. Guidelines for the management of sexually transmitted diseases. World Health Organization, 2003. ISBN: 92 4 154626 3. http:\/\/www.who.int\/hiv\/pub\/sti\/en\/STIGuidelines2003.pdf (accessed 13 Mar 2013)."},{"key":"2024051410042031000_89.Suppl_4.iv52.2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.044164"},{"key":"2024051410042031000_89.Suppl_4.iv52.3","unstructured":"Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales (GRASP): report of 2009 data. Health Protection Report 2010;4."},{"key":"2024051410042031000_89.Suppl_4.iv52.4","first-page":"339","article-title":"Gonococcal antibiotic surveillance in Scotland (GASS): prevalence, patterns and trends in 2009","volume":"25","author":"Eastick","year":"2010","journal-title":"HPS Weekly Report"},{"key":"2024051410042031000_89.Suppl_4.iv52.5","first-page":"29","article-title":"Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae\u2014United States, 1988\u20131991. The Gonococcal Isolate Surveillance Project Study Group","volume":"42","author":"Gorwitz","year":"1993","journal-title":"MMWR CDC Surveill Summ"},{"key":"2024051410042031000_89.Suppl_4.iv52.6","first-page":"143","article-title":"Evaluation of the Australian Gonococcal Surveillance Programme","volume":"29","author":"Samaan","year":"2005","journal-title":"Commun Dis Intell Q Rep"},{"key":"2024051410042031000_89.Suppl_4.iv52.7","first-page":"1","article-title":"Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 1998. The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme","volume":"24","author":"Tapsall","year":"2000","journal-title":"Commun Dis Intell"},{"key":"2024051410042031000_89.Suppl_4.iv52.8","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318232459b"},{"issue":"(Suppl 5S)","key":"2024051410042031000_89.Suppl_4.iv52.9","first-page":"1S","article-title":"Antibiotic-resistant strains of Neisseria gonorrhoeae: policy guidelines for detection, management and control","volume":"36","author":"Centre for Disease Control and Prevention (CDC)","year":"1987","journal-title":"MMWR"},{"key":"2024051410042031000_89.Suppl_4.iv52.10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3201\/eid1108.050157","article-title":"Optimizing treatment of antimicrobial-resistant Neisseria gonorrhoeae","volume":"11","author":"Roy","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"2024051410042031000_89.Suppl_4.iv52.11","first-page":"590","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024051410042031000_89.Suppl_4.iv52.12","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.011267"},{"key":"2024051410042031000_89.Suppl_4.iv52.13","doi-asserted-by":"publisher","DOI":"10.1177\/0956462412472837"},{"issue":"(No. RR-12)","key":"2024051410042031000_89.Suppl_4.iv52.14","first-page":"49","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR"},{"key":"2024051410042031000_89.Suppl_4.iv52.15","unstructured":"GRASP Steering Group. The gonococcal resistance to antimicrobials programme (GRASP) year 2010 report. London: Health Protection Agency, 2011. http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1316016752917 (accessed 4 May 2013)."},{"key":"2024051410042031000_89.Suppl_4.iv52.16","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3181bf575c"},{"key":"2024051410042031000_89.Suppl_4.iv52.17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq476"},{"key":"2024051410042031000_89.Suppl_4.iv52.18","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.042648"},{"key":"2024051410042031000_89.Suppl_4.iv52.19","unstructured":"World Health Organization (WHO), Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO, 2012:1\u201336. http:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/9789241503501 (accessed 4 May 2013)."},{"key":"2024051410042031000_89.Suppl_4.iv52.20","unstructured":"Centers for Disease Control and Prevention (CDC). Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. 2012:1\u201343. http:\/\/www.cdc.gov\/std\/gonorrhea\/default.htm (accessed 4 May 2013)."},{"key":"2024051410042031000_89.Suppl_4.iv52.21","unstructured":"European Centre for Disease Prevention and Control (ECDC). Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe. Stockholm: ECDC, 2012:1\u201323. http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/1206-ECDC-MDR-gonorrhoea-response-plan.pdf (accessed 4 May 2013)."},{"key":"2024051410042031000_89.Suppl_4.iv52.22","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.63"},{"key":"2024051410042031000_89.Suppl_4.iv52.23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq289"},{"key":"2024051410042031000_89.Suppl_4.iv52.24","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.042317"},{"key":"2024051410042031000_89.Suppl_4.iv52.25","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.035337"},{"issue":"(Suppl 1)","key":"2024051410042031000_89.Suppl_4.iv52.26","first-page":"52","article-title":"Gonococcal infection. Sexually transmitted infections, diagnosis and treatment guidelines 2011","volume":"22","author":"Japanese Society of Sexually Transmitted Infection","year":"2011","journal-title":"Jpn J Sex Transm Dis"},{"key":"2024051410042031000_89.Suppl_4.iv52.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2008.02100.x"},{"key":"2024051410042031000_89.Suppl_4.iv52.28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/AAC.15.4.587","article-title":"Pharmacokinetic determinants of penicillin cure of gonococcal urethritis","volume":"15","author":"Jaffe","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"2024051410042031000_89.Suppl_4.iv52.29","unstructured":"European Centre for Disease Prevention and Control (ECDC). Gonococcal antimicrobial susceptibility surveillance in Europe 2010. Stockholm: ECDC, 2012. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/1206-Gonococcal-AMR.pdf (accessed 4 May 2013)."},{"key":"2024051410042031000_89.Suppl_4.iv52.30","doi-asserted-by":"crossref","first-page":"p11=19792","DOI":"10.2807\/ese.16.06.19792-en","article-title":"Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010","volume":"16","author":"Unemo","year":"2011","journal-title":"Euro Surveill"},{"key":"2024051410042031000_89.Suppl_4.iv52.31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00325-11"},{"key":"2024051410042031000_89.Suppl_4.iv52.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05760-11"},{"key":"2024051410042031000_89.Suppl_4.iv52.33","doi-asserted-by":"crossref","first-page":"pii=19721","DOI":"10.2807\/ese.15.47.19721-en","article-title":"Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010","volume":"15","author":"Unemo","year":"2010","journal-title":"Euro Surveill"},{"key":"2024051410042031000_89.Suppl_4.iv52.34","doi-asserted-by":"crossref","first-page":"pii=19833","DOI":"10.2807\/ese.16.14.19833-en","article-title":"Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010","volume":"16","author":"Ison","year":"2011","journal-title":"Euro Surveill"},{"key":"2024051410042031000_89.Suppl_4.iv52.35","doi-asserted-by":"crossref","first-page":"pii=19998","DOI":"10.2807\/ese.16.43.19998-en","article-title":"First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria","volume":"16","author":"Unemo","year":"2011","journal-title":"Euro Surveill"},{"key":"2024051410042031000_89.Suppl_4.iv52.36","doi-asserted-by":"crossref","first-page":"pii=20200","DOI":"10.2807\/ese.17.25.20200-en","article-title":"Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011","volume":"17","author":"Unemo","year":"2012","journal-title":"Euro Surveill"},{"key":"2024051410042031000_89.Suppl_4.iv52.37","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt034"},{"key":"2024051410042031000_89.Suppl_4.iv52.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.176575"},{"key":"2024051410042031000_89.Suppl_4.iv52.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-006-0445-z"},{"key":"2024051410042031000_89.Suppl_4.iv52.40","doi-asserted-by":"publisher","DOI":"10.1258\/095646207781568556"},{"key":"2024051410042031000_89.Suppl_4.iv52.41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit084"},{"key":"2024051410042031000_89.Suppl_4.iv52.42","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks449"},{"key":"2024051410042031000_89.Suppl_4.iv52.43","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn235"},{"key":"2024051410042031000_89.Suppl_4.iv52.44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00309-10"},{"key":"2024051410042031000_89.Suppl_4.iv52.45","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp118"},{"key":"2024051410042031000_89.Suppl_4.iv52.46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01506-09"},{"key":"2024051410042031000_89.Suppl_4.iv52.47","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir929"},{"key":"2024051410042031000_89.Suppl_4.iv52.48","doi-asserted-by":"crossref","unstructured":"Kirkcaldy RD . Treatment of gonorrhoea in an era of emerging cephalosporin resistance and results of a randomized trial of new potential treatment options, STI & AIDS World Congress 2013. Vienna, Austria, 14\u201317 July 2013. Abstract SO8.1.","DOI":"10.1136\/sextrans-2013-051184.0043"},{"key":"2024051410042031000_89.Suppl_4.iv52.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.06.006"},{"key":"2024051410042031000_89.Suppl_4.iv52.50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00036-12"},{"key":"2024051410042031000_89.Suppl_4.iv52.51","unstructured":"Hook E III Oldach D Jamieson B . A phase 2 study to evaluate the efficacy and safety of single dose solithromycin (CEM-101) for the treatment of patients with uncomplicated urogenital gonorrhoea. European Congress of Clinical Microbiology and Infectious Disease Berlin 2013 Abstract O274."},{"key":"2024051410042031000_89.Suppl_4.iv52.52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06219.x"},{"key":"2024051410042031000_89.Suppl_4.iv52.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2008.04.009"},{"key":"2024051410042031000_89.Suppl_4.iv52.54","doi-asserted-by":"crossref","first-page":"pii=20444","DOI":"10.2807\/1560-7917.ES2013.18.14.20444","article-title":"Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain","volume":"18","author":"Goire","year":"2013","journal-title":"Euro Surveill"},{"key":"2024051410042031000_89.Suppl_4.iv52.55","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-937-2_22"},{"key":"2024051410042031000_89.Suppl_4.iv52.56","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.117"},{"key":"2024051410042031000_89.Suppl_4.iv52.57","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00124"},{"key":"2024051410042031000_89.Suppl_4.iv52.58","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00123"},{"key":"2024051410042031000_89.Suppl_4.iv52.59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"2024051410042031000_89.Suppl_4.iv52.60","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-0011-3"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2012-050913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T17:05:07Z","timestamp":1715706307000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2012-050913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,8]]},"references-count":60,"journal-issue":{"issue":"Suppl 4","published-online":{"date-parts":[[2013,11,15]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1136\/sextrans-2012-050913"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2012-050913","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,8]]}}}